Marshall Wace
AKBA icon

Marshall Wace’s Akebia Therapeutics AKBA Stock Holding History

Marshall Wace’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-247,069
Closed -$252K – 2453
2024
Q2 		$252K Sell
247,069
-776,206
-76% -$959K ﹤0.01% 2223
2024
Q1 		$1.87M Buy
+1,023,275
New +$1.64M ﹤0.01% 1396
2022
Q4 		– Sell
-314,316
Closed -$101K – 2895
2022
Q3 		$101K Buy
+314,316
New +$123K ﹤0.01% 3179
2022
Q1 		– Sell
-4,475,138
Closed -$10.1M – 3293
2021
Q4 		$10.1M Sell
4,475,138
-2,493,673
-36% -$6.8M 0.02% 853
2021
Q3 		$20.1M Buy
6,968,811
+2,859,222
+70% +$8.16M 0.08% 267
2021
Q2 		$15.6M Buy
+4,109,589
New +$13.8M 0.07% 307
2020
Q4 		– Sell
-38,578
Closed -$97K – 1844
2020
Q3 		$97K Sell
38,578
-322,389
-89% -$2.83M ﹤0.01% 1518
2020
Q2 		$4.9M Buy
+360,967
New +$3.73M 0.03% 479
2019
Q2 		– Sell
-37,263
Closed -$305K – 1310
2019
Q1 		$305K Sell
37,263
-496,678
-93% -$3.41M ﹤0.01% 1260
2018
Q4 		$2.95M Sell
533,941
-5,123
-1% -$40.1K 0.03% 628
2018
Q3 		$4.76M Sell
539,064
-195
-0% -$1.74K 0.04% 462
2018
Q2 		$5.38M Buy
539,259
+304,490
+130% +$3.05M 0.08% 282
2018
Q1 		$2.24M Buy
234,769
+30,573
+15% +$428K 0.09% 180
2017
Q4 		$3.04M Buy
204,196
+114,349
+127% +$1.9M 0.13% 147
2017
Q3 		$1.8M Sell
89,847
-7,447
-8% -$114K 0.08% 171
2017
Q2 		$1.36M Buy
97,294
+44,577
+85% +$565K 0.06% 156
2017
Q1 		$474K Sell
52,717
-635,753
-92% -$6.21M 0.02% 248
2016
Q4 		$7.17M Buy
688,470
+66,620
+11% +$574K 0.05% 398
2016
Q3 		$5.63M Buy
621,850
+160,333
+35% +$1.36M 0.04% 386
2016
Q2 		$3.45M Buy
461,517
+6,911
+2% +$60.3K 0.03% 473
2016
Q1 		$4.1M Buy
454,606
+82,931
+22% +$672K 0.04% 391
2015
Q4 		$4.8M Sell
371,675
-56,357
-13% -$575K 0.05% 390
2015
Q3 		$4.13M Buy
428,032
+28,032
+7% +$257K 0.05% 325
2015
Q2 		$4.12M Buy
+400,000
New +$3.41M 0.05% 329

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's AKBA Position: Q3 2024 in Review

Marshall Wace sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 247,069 shares — an estimated $252K sold.

Marshall Wace first reported a position in AKBA in Q2 2015 and held it in 24 quarters. The position peaked at $20.1M in Q3 2021. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Marshall Wace reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Marshall Wace sold 247,069 Akebia Therapeutics shares in Q3 2024, an estimated $252K.
  • Marshall Wace first reported a position in Akebia Therapeutics in Q2 2015 and held it in 24 quarters.
  • Marshall Wace's Akebia Therapeutics position peaked at $20.1M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.